16 Result(s)
within
Ralf Gutzmer
Oncology
-
Article
Kutane Nebenwirkungen onkologischer Systemtherapien
Bestimmte medikamentöse Tumortherapien verursachen kutane Toxizität an Händen, Füßen und Nägeln.
-
Article
Open AccessPreferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors’ perspective
Adjuvant treatment with immune checkpoint inhibitors, such as PD1-antibodies (ICI) ± CTLA4-antibodies (cICI) or targeted therapy with BRAF/MEK inhibitors (TT), has shown a significant improvement in disease-fr...
-
Article
Medikamentöse Therapie des inoperablen Melanoms
Etablierte Therapieverfahren für das inoperable Melanom sind die Immuncheckpointinhibition mit Inhibitoren von CTLA‑4 („cytotoxic T‑lymphocyte-associated protein 4“), PD‑1 („programmed cell death protein 1“) u...
-
Article
Situation klinischer Studien in Deutschland – ein interdisziplinäres Positionspapier
-
Article
Open AccessAssessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis
The BOLT study for sonidegib, a Hedgehog pathway inhibitor (HHI) approved for patients with locally advanced basal cell carcinoma (laBCC) not amenable to curative surgery or radiotherapy, used modified Respons...
-
Article
Open AccessPatterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)
Uveal melanoma (UM) is an orphan cancer of high unmet medical need. Current patterns of care and surveillance remain unclear as they are situated in an interdisciplinary setting.
-
Article
Vorgehen beim Basalzellkarzinom
Das Basalzellkarzinom ist der häufigste Tumor des hellhäutigen Menschen.
-
Article
Open AccessLong-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Ipilimumab has shown long-term overall survival (OS) in patients with advanced melanoma in clinical trials, but robust real-world evidence is lacking. We present long-term outcomes from the IMAGE study (NCT015...
-
Article
Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases
PD-1 inhibition (PD-1i) is the standard of care in melanoma and other malignancies. In patients with bone metastases of solid tumors, the monoclonal antibody denosumab directed against RANKL is approved for th...
-
Article
Hedgehog Pathway Inhibition for the Treatment of Basal Cell Carcinoma
Globally, basal cell carcinoma is the most commonly diagnosed cancer. While most cases are amenable to surgery, treatment options for advanced basal cell carcinoma, including locally advanced basal cell carcin...
-
Article
First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis
Inhibition of the mitogen-activated protein kinase (MAPK) pathway as well as programmed death 1 receptor (PD-1) blockade was shown to prolong overall survival (OS) in patients with advanced B-Raf proto-oncogen...
-
Article
Malignes Melanom − Früherkennung, Diagnostik und Nachsorge
Das maligne Melanom ist eine häufige Hautkrebsart mit einer sehr hohen Mortalität. In Europa versterben jährlich etwa 22.000 Menschen daran, davon etwa 2700 Patienten alleine in Deutschland. Die Inzidenz zeigt...
-
Article
Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders
Ipilimumab and programmed death (PD) 1-antibodies are effective treatment options in metastatic melanoma. The safety and efficacy of ipilimumab in patients with pre-existing autoimmune disorders (AD) has only ...
-
Article
Open AccessClinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients
Concomitant radiation with BRAF inhibitor (BRAFi) therapy may increase radiation-induced side effects but also potentially improve tumour control in melanoma patients.
-
Article
Open AccessTreatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study
Aviscumine, a recombinant plant protein, is an immune modulator that induces ribotoxic stress at the 28S ribosomal RNA subunit. In this way cytokine release and T-cell responses are enhanced. This phase II tri...
-
Article
Criteria in Sentinel Lymph Nodes of Melanoma Patients that Predict Involvement of Nonsentinel Lymph Nodes
Previous studies described various criteria in sentinel lymph nodes (SLN) of melanoma patients that predict the involvement of further, nonsentinel lymph nodes (NSLN). Such criteria may facilitate the selectio...
